Galapagos Ditched This Drug. Now It Just Raised $125 Million.

COL-5671 targets something called SIK3 (salt-inducible kinase 3). If that means nothing to you, think of SIK3 as a light switch inside immune cells that controls two things simultaneously.

When you flip this switch off with the drug, two things happen. First, the immune system dials down its production of inflammatory molecules like TNFα, IL-12, and IL-23 (the chemicals that drive autoimmune flares). Second, it ramps up production of IL-10, a molecule that calms the immune system down.

It's like having a thermostat that both turns off the heater and turns on the AC at the same time. Most existing drugs only do one or the other. They block a single inflammatory signal but don't actively promote resolution. COL-5671 theoretically does both, in one pill, taken once a day.

That dual mechanism is what investors are paying $125 million to test in humans.

The Oral Advantage in a Needle-Dominated World

Coultreon's drug enters a crowded immunology market, but it has one major structural advantage: it's a pill.

The biggest drugs in autoimmune disease (think Humira, Stelara, Skyrizi) are all injectable biologics. Patients have to give themselves shots every few weeks, often with drugs that cost tens of thousands of dollars per year. Oral drugs are cheaper to manufacture, easier to take, and don't require cold-chain shipping.

The oral immunology space already has some players. JAK inhibitors like Rinvoq (upadacitinib) and the newer TYK2 inhibitor Sotyktu (deucravacitinib) have proven that pills can compete with biologics. But JAK inhibitors carry safety baggage: black box warnings about blood clots, infections, and cancer risk that make doctors hesitant.

COL-5671 takes a completely different approach from JAK inhibitors. By working through the SIK3 pathway, it could potentially sidestep those safety concerns entirely. That "potentially" is doing a lot of heavy lifting, though; the drug is still in Phase 1, so safety data in larger groups remains years away.

The Road to Proof

Coultreon plans to advance COL-5671 into Phase 2 trials for psoriasis and ulcerative colitis, with proof-of-concept data expected in 2027. The target list also includes Crohn's disease, psoriatic arthritis, and rheumatoid arthritis, though those are further out.

If the science works, Coultreon would essentially be offering a single oral drug that mimics what currently takes multiple expensive biologics to achieve. That's a big "if," but it explains why Novo Holdings' partner Max Klement joined the board, and why Regeneron's venture arm wrote a check.

What This Tells Us About Biotech Right Now

Coultreon's raise fits a growing pattern. Big pharma companies are shedding assets during restructurings, and nimble startups are scooping them up with venture backing. Bristol Myers Squibb's cast-off autoimmune assets launched Beeline Medicines with $300 million. Now Galapagos' discarded SIK3 program has found a $125 million home.

The lesson? In biotech, "abandoned" doesn't always mean "failed." Sometimes it just means the original owner had other problems. Coultreon is betting that Galapagos' loss is their gain, and some very smart money agrees.

Now they just have to prove the drug actually works.

Erasca Hit a Home Run. The Stock Fell 47%.

Erasca's pan-RAS inhibitor posted jaw-dropping early cancer data that analysts called a "home run." Then the stock fell 42% in a single day. A patient death, a patent fight, and transparency questions collided with the best data in Erasca's history.